Dr Karen Alt and Dr Chyn Chua recognised at the ACBD Research Symposium

L-R: Dr Karen Alt and Dr Chyn Chua

Congratulations to Dr Karen Alt and Dr Chryn Chua on receiving the Best Research Paper awards for a researcher and also a clinician at the recent Australian Centre for Blood Diseases (ACBD) Research Symposium held on 11 November 2022.

Focussing principally on the talent within Clinical Haematology and ACBD, the symposium showcased both senior as well as early and mid-career researchers.  CLICK HERE to find out more about all achievements at the ACBD that were highlighted at the symposium.

Head of  NanoTheranostics group, Dr Karen Alt’s research represents a simple self-assembly approach for the fabrication of antibody-decorated metal–organic framework (MOF) nanocrystals with broad potential for sensing, diagnostic imaging, and targeted drug delivery.

Reference:

Alt K, Carraro F, Jap E, Linares-Moreau M, Riccò R, Righetto M, Bogar M, Amenitsch H, Hashad RA, Doonan C, Hagemeyer CE*, Falcaro P* (2022) Self-assembly of oriented antibody-decorated metal-organic framework nanocrystals for active-targeting applications. Advanced Materials 34:e2106607

ACBD PhD student and Haematologist Dr Chyn Chua’s research is on the effects of Venetoclax and Chemotherapy in older patients with Acute Myeloid Leukemia.  

Reference:

Chua CC, Roberts AW, Reynolds J, Fong CY, Ting SB, Salmon J, MacRaild S, Ivey A, Tiong IS, Fleming S, Brown F, Loo S, Majewski IJ, Bohlander S, Wei AH. Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): a phase 1b dose escalation study of venetoclax combined with modified intensive chemotherapy. Journal of Clinical Oncology. (2020) 38:30, 3506-3517. Doi: 10.1200/JCO.20.00572